GlassScriptPhysician profile
Diana Palanker
NPI 1104385988
$1,216.29
in general payments reported to CMS, 2019-2025
14 companies · $886 in 2025
The $886 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $61.04 · 2023: $120 · 2024: $148 · 2025: $886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,155.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $416.52 | 2025 | Auvelity, Symbravo |
| Lilly USA, LLC | $267.71 | 2023-2025 | Mounjaro, Zepbound, Kisunla |
| Paratek Pharmaceuticals, INC. | $202.82 | 2023-2025 | Nuzyra, Xhance |
| Abbvie INC. | $67.63 | 2023-2025 | |
| Novo Nordisk INC | $57.77 | 2025 | Wegovy, Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.80 | 2025 | Xifaxan |
| Medtronic, INC. | $31.74 | 2022 | |
| Intra-Sana Laboratories | $28.47 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Philips North America LLC | $23.61 | 2025 | Ecc Solutions |
| Pfizer INC. | $21.75 | 2023 | |
| Amgen INC. | $18.00 | 2025 | Otezla, Repatha |
| Hikma Pharmaceuticals USA | $16.17 | 2023 | Mitigare, Ryaltris, Kloxxado |
| Ultragenyx Pharmaceutical INC. | $14.78 | 2022 | |
| Glaxosmithkline, LLC. | $14.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Palanker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.